Menu
Menu
With testing volumes higher than 1,000 samples a month, Vitrolife's NGS-plus-many-complementary-tests model was becoming harder to sustain, and the lab needed better detection of complex variants. That combination made the case for a model built to be more efficient, robust, and future ready.
Since moving to the SOPHiA DDM™ Enhanced Clinical Exome Solution, Arantxa points to gains on both sides: a more sensitive test, with CNV and complex variant analysis helping reduce residual risk, and a simpler operational workflow that has cut hands-on time, turnaround times, retesting, and resampling. NGS now pairs with only a small number of complementary tests, bringing all data together in one place for reporting and, where needed, re-analysis.
Watch Arantxa explain, in her own words, what prompted the change and what it's meant for her lab day to day.
To learn more about SOPHiA DDM™ Enhanced Exome Solutions, visit the webpage.
For Research Use Only. Not for use in diagnostic procedures.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
